Subject: ECO
The Government of Canada invests over $21M in innovative health research
Minister Philpott visits Laval University to meet with top researchers who have joined forces in the fight against HIV/AIDS and other diseases
QUÉBEC CITY, Aug. 21, 2017 /CNW/ - Researchers from Laval University and from across the country are working hard to create new scientific knowledge and tackle some of today's most pressing health issues that affect Canadians.
Today, the honourable Jane Philpott, Minister of Health, was at the CHU de Québec ? Laval University Research Centre, to highlight a total investment of over $21M in cutting-edge research from the Canadian Institutes of Health Research.
Twelve researchers, including two from Laval University, received $2.9M to undertake innovative biomedical and clinical HIV vaccine research projects. Furthermore, Dr. Gary Kobinger, renowned for his work on the world's first effective vaccine against the Ebola virus, received a $3.9M grant to work on a vaccine to prevent HIV. The Minister took the opportunity to commend a further 18 researchers from Laval University who received a total of $14.4M in funding to tackle conditions such as heart disease, asthma and cancer.
The Minister was joined by her Parliamentary Secretary, Joël Lightbound. During their visit, they had an opportunity to meet with researchers to learn about their projects, and participate in a lab tour.
Quotes
"It's always a great experience to meet with researchers who are at the forefront of creating the new scientific knowledge needed to treat illnesses, eradicate viruses like HIV, and improve quality of life. The researchers working at Laval University are a source of great inspiration to Canadians. We all benefit from their hard work."
Jane Philpott
Minister of Health
"The brilliant researchers working at the CHU de Québec ? Laval University Research Centre have helped put Laval University on the international stage for leading-edge scientific research. The projects funded through CIHR will improve the human condition by tackling some of the most devastating health issues of our time. The researchers being celebrated today should be very proud of what they are accomplishing."
Joël Lightbound
Parliamentary Secretary to the Minister of Health
Member of Parliament for Louis-Hébert
"I wish to congratulate the most recent recipients of CIHR funding working at CHU de Québec ? Laval University Research Centre. Each of your projects shows tremendous potential for adding to the scientific knowledge we have about conditions such as asthma, heart disease, cancer and HIV/AIDS. Thank you for your contributions to health research and to building a healthier Canada."
Dr. Marc Ouellette
Scientific Director, CIHR Institute of Infection and Immunity
Quick Facts
- CIHR has provided 12 grants in the area of biomedical and clinical HIV/AIDS research for a total investment of $2.9M. These grants are designed to support cutting-edge biomedical and clinical research related to the development of an HIV vaccine.
- CIHR has awarded a grant of $3.9M to Laval University's Dr. Gary Kobinger to work towards developing a safe and effective HIV vaccine.
- Today's announced research projects are partly funded by the CIHR HIV/AIDS Research Initiative, which is the research arm of the Federal Initiative to Address HIV/AIDS in Canada. It invests $21 million each year to support research, capacity building and knowledge translation activities in four key areas: Biomedical and clinical research; Health services and population health research; Community-Based Research; and the CIHR Canadian HIV Trials Network (CTN).
- Project Grants are designed to support researchers at any career stage build and conduct health research and knowledge translation projects covering a range of areas, from discovery science and clinical research to strengthening the health care system and examining the social determinants of health. In the most recent Project Grant competition, CIHR provided $14.4M to support 18 researchers affiliated at Laval University.
Related Products
Backgrounder ? Biomedical and clinical HIV/AIDS research grants
Backgrounder ? Operating Grant: Optimizing the VSV Vector towards an HIV Vaccine
Backgrounder ? Project Grants
Backgrounder ? Dr. Kobinger's research
CIHR HIV/AIDS Initiative
Federal Initiative to Address HIV/AIDS in Canada
At the Canadian Institutes of Health Research (CIHR) we know that research has the power to change lives. As Canada's health research investment agency, we collaborate with partners and researchers to support the discoveries and innovations that improve our health and strengthen our health care system.
Backgrounder
Operating Grant: Innovative Biomedical and Clinical HIV/AIDS Research
Through new CIHR funding, researchers will undertake innovative biomedical and clinical HIV vaccine research projects in new areas of investigation or take previous discoveries in new directions; promote the development and testing of novel HIV vaccine research tools and methodologies; and support high-risk HIV vaccine research projects with the potential for high impact, breakthrough and/or transformative advances.
A total of ten researchers and two new investigators from across the country were awarded $2.9M dollars for the following projects:
|
Researcher |
Institution |
Project Title |
Amount |
|
Dr. Petronela Ancuta |
Centre hospitalier de l'Université de Montréal (CHUM)
|
Targeting mTOR to restore mucosal immunity toward remission in HIV-infected individuals |
$250,000 |
|
Dr. Eric Arts |
University of Western Ontario
|
Developing the ACT-VEC as an HIV therapeutic vaccine and cure approach |
$250,000 |
|
Dr. Dimitrios Dikeakos |
University of Western Ontario
|
Nef Inhibitors as Adjuvants Towards a Cure |
$247,755 |
|
Dr. Jérôme Estaquier |
Université Laval
|
Role of follicular CD8 T cells in the control of HIV/SIV mucosal immunity.
|
$250,000 |
|
Dr. Daniel E Kaufmann |
Centre hospitalier de l'Université de Montréal (CHUM)
|
Influence of pre-existing HIV cross-reactive CD4 T cells on vaccine responses to new Env immunogens |
$249,994 |
|
Dr. Charu Kaushic |
McMaster University
|
Improving vaginal health to decrease biological risk of HIV-1 infection in Canadian ACB women
|
$250,000 |
|
Dr. Denis Leclerc |
Université Laval
|
Adjuvantization of SIV antigens using a novel toll like receptor 7 (TLR7) agonist: A proof of concept in non-human primate.
|
$250,000 |
|
Dr. Lyle R Mckinnon |
University of Manitoba
|
Impact of Vedolizumab on immune cell homing to the female reproductive and gastrointestinal mucosa
|
$249,460 |
|
Dr. Mario A Ostrowski |
University of Toronto
|
Developing a Novel Modular Nanoparticle Vaccine Strategy to Induce Durable Systemic and Mucosal HIV Envelope Specific Antibodies
|
$250,000 |
|
Dr. Jean-Pierre Routy |
Research Institute of the McGill University Health Centre
|
Locking out HIV from CD4 T cells: A pilot study of the impact of anti a4b7 antibody (vedolizumab) on viral control following analytical treatment interruption
|
$247,650 |
|
Adam Burgener |
University of Manitoba |
Mechanisms of metaproteome factors in HIV infection risk in young women |
$249,888 |
|
Ruey-Chyi |
University of Manitoba |
Elucidating the role of cell homing pathways in controlling endothelial cell-mediated enhancement of resting CD4+ T cell infection by HIV |
$206,600 |
Backgrounder
Operating Grant: Optimizing the VSV Vector towards an HIV Vaccine
|
Researcher |
Institution |
Project Title |
Amount |
|
Dr. Gary Kobinger |
Laval University
|
Development of a safe, effective and clinically acceptable VSV-based HIV vaccine |
$3,997, 503 |
Backgrounder
Project Grants
Project Grants are designed to support researchers at any career stage build and conduct health research and knowledge translation projects covering a range of areas, from discovery science and clinical research to strengthening the health care system and examining the social determinants of health.
In the most recent Project Grants competition, CIHR provided $14.4M to support 18 researchers at Laval University.
|
Researcher |
Project |
Funding Amount |
|
Dr. Patrick Archambault |
|
$1.47M |
|
Dr. Jean-François Bilodeau |
|
$662,000 |
|
Dr. Elyse Bissonnette |
|
$643,000 |
|
Dr. Mohamed Chahine |
|
$1.03M |
|
Dr. Paul De Koninck |
|
$784,000 |
|
Dr. Sabine Elowe |
Towards a comprehensive model of Spindle Assembly Checkpoint silencing
|
$536,000 |
|
Dr. Amélie Fradet-Turcotte
|
Defining the molecular basis of chemoradiation sensitivity in HPV+ head and neck cancers.
|
$696,000 |
|
Dr. Chantal Guillemette |
Function of the glucuronosyltransferase pathway in chronic lymphocytic leukemia
|
$639,000 |
|
Dr. Samer Hussein |
The role of long non-coding RNAs in defining pluripotent stem cell states
|
$799,000 |
|
Dr. Mathieu Laplante |
Molecular mechanisms of adipose tissue development
|
$696,000 |
|
Dr. Jean-Yves Masson |
Roles of the tumor suppressor PALB2 at the crossroads of DNA double-strand break repair and synthetic lethal strategies
|
$968,000 |
|
Dr. Donald Poirier |
Développement d'un traitement sélectif de l'endométriose : Étude du potentiel du premier inhibiteur irréversible de la 17beta-HSD1 chez le primate
|
$363,000 |
|
Dr. Armen Saghatelyan |
Deciphering the role of autophagy in neuronal migration and maturation
|
$991,000 |
|
Dr. François Gros-Louis |
Pathogenic Pathways and in-vitro modelization of Intracranial Aneurysms in populations of Inuit and French Canadian descent
|
$952,425 |
|
Dr. Sébastien Hébert |
microRNA-132: from underlying mechanism of neurodegeneration to therapeutic application in Huntington's disease
|
$573,750 |
|
Dr. Michel G Maziade |
Intercepting the "childhood risk syndrome" of schizophrenia and mood disorders along the developmental trajectory: A preclinical staging of children and adolescents at genetic risk
|
$852,975 |
|
Dr. Thomas Moss |
Mechanism of Ribosomal RNA Gene Silencing and Its Roles in Pluripotency and Cancer
|
$1,074,060 |
|
Dr. Martin Parent |
La modulation des ganglions de la base par les afférences neurochimiques du tronc cérébral: implication dans la physiopathologie des troubles du mouvement
|
$738,225 |
SOURCE Canadian Institutes of Health Research
These press releases may also interest you
|
News published on and distributed by:
